SCHWARTZ BRIAN 4
4 · Cyclacel Pharmaceuticals, Inc. · Filed Jan 31, 2024
Insider Transaction Report
Form 4
SCHWARTZ BRIAN
Director
Transactions
- Award
Common Stock
2024-01-29+12,500→ 15,205 total - Award
Stock Option (right to buy)
2024-01-29+12,500→ 12,500 totalExercise: $2.28Exp: 2034-01-29→ Common Stock (12,500 underlying)
Footnotes (3)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.
- [F3]The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.